Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $196.00

Ascendis Pharma A/S (NASDAQ:ASND) had its target price hoisted by equities researchers at Jefferies Financial Group from $174.00 to $196.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Jefferies Financial Group’s target price points to a potential upside of 42.15% from the stock’s previous close.

A number of other brokerages have also weighed in on ASND. JPMorgan Chase & Co. boosted their price objective on shares of Ascendis Pharma A/S from $167.00 to $170.00 and gave the company an “overweight” rating in a report on Friday, May 3rd. The Goldman Sachs Group upped their price target on shares of Ascendis Pharma A/S from $170.00 to $195.00 and gave the company a “buy” rating in a report on Tuesday. Stifel Nicolaus started coverage on shares of Ascendis Pharma A/S in a report on Friday, May 31st. They issued a “buy” rating and a $200.00 price target on the stock. TD Cowen raised shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating and increased their target price for the stock from $156.00 to $175.00 in a research note on Tuesday, June 25th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $173.00 price objective on shares of Ascendis Pharma A/S in a report on Wednesday, May 15th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $184.64.

Ascendis Pharma A/S Trading Up 7.3 %

Shares of ASND stock traded up $9.40 during trading hours on Tuesday, reaching $137.88. 405,776 shares of the company’s stock were exchanged, compared to its average volume of 369,078. The company has a market cap of $8.03 billion, a price-to-earnings ratio of -14.41 and a beta of 0.63. Ascendis Pharma A/S has a fifty-two week low of $85.29 and a fifty-two week high of $161.00. The stock’s 50 day moving average is $132.69 and its 200-day moving average is $138.97.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Westfield Capital Management Co. LP lifted its position in Ascendis Pharma A/S by 1.1% in the first quarter. Westfield Capital Management Co. LP now owns 4,075,214 shares of the biotechnology company’s stock valued at $616,050,000 after acquiring an additional 44,580 shares during the last quarter. Avoro Capital Advisors LLC lifted its position in Ascendis Pharma A/S by 5.6% in the first quarter. Avoro Capital Advisors LLC now owns 3,966,666 shares of the biotechnology company’s stock valued at $599,641,000 after acquiring an additional 211,111 shares during the last quarter. Capital International Investors lifted its position in Ascendis Pharma A/S by 0.5% in the first quarter. Capital International Investors now owns 2,191,312 shares of the biotechnology company’s stock valued at $331,261,000 after acquiring an additional 10,044 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in Ascendis Pharma A/S by 23.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock valued at $269,374,000 after acquiring an additional 336,976 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its position in Ascendis Pharma A/S by 5.8% in the second quarter. Massachusetts Financial Services Co. MA now owns 1,711,015 shares of the biotechnology company’s stock valued at $233,348,000 after acquiring an additional 93,185 shares during the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.